Raymond James Financial Inc Ab Cellera Biologics Inc. Transaction History
Raymond James Financial Inc
- $299 Billion
- Q3 2025
A detailed history of Raymond James Financial Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 38,418 shares of ABCL stock, worth $141,762. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,418
Previous 28,049
36.97%
Holding current value
$141,762
Previous $96,000
101.04%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ABCL
# of Institutions
168Shares Held
109MCall Options Held
1.26MPut Options Held
788K-
Baker Bros. Advisors LP New York, NY27.5MShares$102 Million1.13% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$49.3 Million0.01% of portfolio
-
Baillie Gifford & CO10.4MShares$38.5 Million0.04% of portfolio
-
Two Sigma Investments, LP New York, NY5.18MShares$19.1 Million0.04% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny4.8MShares$17.7 Million0.05% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.05B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...